Physician profile
Emily Smith
NPI 1457973984
$1,415.17
in general payments reported to CMS, 2019-2025
11 companies · $498 in 2025
The $498 reported for 2025 was more than what 77% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $63.78 · 2022: $408 · 2023: $387 · 2024: $57.79 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $943.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $343.31 | 2022-2025 | Istent Infinite, Photrexa |
| Sight Sciences, INC. | $233.44 | 2022-2023 | Tearcare System |
| Alcon Vision LLC | $150.53 | 2021-2025 | Precision 1, Total30, Dailies Total1 |
| Tarsus Pharmaceuticals, INC. | $150.00 | 2025 | Xdemvy |
| Astellas Pharma US INC | $125.25 | 2025 | Izervay |
| Abbvie INC. | $125.00 | 2023 | Durysta |
| Coopervision INC. | $100.74 | 2021-2024 | Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $97.25 | 2022-2025 | Infuse |
| Johnson & Johnson Vision Care, INC. | $46.04 | 2022-2025 | |
| Biotissue Holdings INC. | $24.97 | 2022 | |
| Harrow Eye, LLC | $18.64 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.